SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Summary

The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.

Timeline

Start

2016-12-05

Primary completion

2019-03-18

Completion

2019-03-18

Publications

• Creange A, Hutin E, Sedel F, Le Vigouroux L, Lefaucheur JP. High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study. BMC Neurol. 2023 Oct 30;23(1):389. doi: 10.1186/s12883-023-03440-y.

Drugs

Indications